A humanised Fc‐disabled immunoglobulin G1 monoclonal antibody against IL‐7Rα is also being evaluated for treating autoimmune diseases, with the anticipation that it will effectively block the actions of both TSLP and IL‐7.10 Here, TSLP is linked to autoimmune disease.